Search Results - "Leighl, N. B."

Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study by Leighl, N B, Bennouna, J, Yi, J, Moore, N, Hambleton, J, Hurwitz, H

“…Background: Bevacizumab provides clinical benefit in multiple solid tumours, but is associated with some increase in bleeding risk. Thrombotic events…”
Get full text

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer by Pallis, A G, Fennell, D A, Szutowicz, E, Leighl, N B, Greillier, L, Dziadziuszko, R

“…Non-small-cell lung cancer (NSCLC) remains by far the major cause of cancer-related death in the Western world in both men and women. The majority of patients…”
Get full text

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer by Chen, H, Modiano, M R, Neal, J W, Brahmer, J R, Rigas, J R, Jotte, R M, Leighl, N B, Riess, J W, Kuo, C J, Liu, L, Gao, B, DiCioccio, A T, Adjei, A A, Wakelee, H A

“…Background: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC)…”
Get full text

An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer by Horgan, A.M., Bradbury, P.A., Amir, E., Ng, R., Douillard, J.Y., Kim, E.S., Shepherd, F.A., Leighl, N.B.

“…The INTEREST (IRESSA NSCLC Trial Evaluating Response and Survival against Taxotere) trial compared gefitinib with docetaxel (Taxotere) in pretreated advanced…”
Get full text

Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer by Leighl, N B, Shepherd, F A, Zawisza, D, Burkes, R L, Feld, R, Waldron, J, Sun, A, Payne, D, Bezjak, A, Tattersall, M H N

“…We developed a decision aid (DA) for patients with metastatic non-small cell lung cancer (NSCLC), to better inform patients of their prognosis and treatment…”
Get full text

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours by Diaz-Padilla, I, Siu, L L, San Pedro-Salcedo, M, Razak, A R A, Colevas, A D, Shepherd, F A, Leighl, N B, Neal, J W, Thibault, A, Liu, L, Lisano, J, Gao, B, Lawson, E B, Wakelee, H A

“…Background: To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of…”
Get full text

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line by Leighl, N B

“…Metastatic non-small-cell lung cancer (nsclc) is the leading cause of cancer mortality in Canada. Although treatment outcomes in advanced disease remain…”
Get full text

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial by Hui, R., Garon, E.B., Goldman, J.W., Leighl, N.B., Hellmann, M.D., Patnaik, A., Gandhi, L., Eder, J.P., Ahn, M.-J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G.M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N.A.

“…Pembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1)…”
Get full text

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer by Lim, C., Tsao, M.S., Le, L.W., Shepherd, F.A., Feld, R., Burkes, R.L., Liu, G., Kamel-Reid, S., Hwang, D., Tanguay, J., da Cunha Santos, G., Leighl, N.B.

“…Testing for EGFR mutations and ALK rearrangement has become standard in managing advanced nonsmall-cell lung cancer (NSCLC). However, many institutions in…”
Get full text

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer by Schoenfeld, A.J., Antonia, S.J., Awad, M.M., Felip, E., Gainor, J., Gettinger, S.N., Hodi, F.S., Johnson, M.L., Leighl, N.B., Lovly, C.M., Mok, T., Perol, M., Reck, M., Solomon, B., Soria, J.-C., Tan, D.S.W., Peters, S., Hellmann, M.D.

“…Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC),…”
Get full text

Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival by Wakeam, E, Acuna, S.A, Leighl, N.B, Giuliani, M.E, Finlayson, S.R.G, Varghese, T.K, Darling, G.E

“…Highlights • We report a propensity- and stage-matched comparison of surgery vs. non-surgical treatment for SCLC. • Surgery was associated with longer survival…”
Get full text

Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer by Wakeam, E, Varghese, T.K, Leighl, N.B, Giuliani, M, Finlayson, S.R.G, Darling, G.E

“…Graphical abstract…”
Get full text

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials by O'Kane, G M, Barnes, T A, Leighl, N B

“…Tumours with sensitizing mutations in the gene constitute a distinct molecular subgroup of non-small-cell lung cancers (nsclcs) that benefit from precision…”
Get full text

Canadian consensus: a new systemic treatment algorithm for advanced EGFR- mutated non-small-cell lung cancer by Melosky, B, Banerji, S, Blais, N, Chu, Q, Juergens, R, Leighl, N B, Liu, G, Cheema, P

“…Multiple clinical trials for the treatment of advanced mutated non-small-cell lung cancer (nsclc) have recently been reported. As a result, the treatment…”
Get full text

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer by Fung, A.S., Graham, D.M., Chen, E.X., Stockley, T.L., Zhang, T., Le, L.W., Albaba, H., Pisters, K.M., Bradbury, P.A., Trinkaus, M., Chan, M., Arif, S., Zurawska, U., Rothenstein, J., Zawisza, D., Effendi, S., Gill, S., Sawczak, M., Law, J.H., Leighl, N.B.

“…•Recommended phase II dose is binimetinib 30 mg BID with carboplatin/pemetrexed in non-squamous NSCLC.•Manageable toxicities observed with the combination of…”
Get full text

Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR- mutated non-small-cell lung cancer by Cheema, P K, Gomes, M, Banerji, S, Joubert, P, Leighl, N B, Melosky, B, Sheffield, B S, Stockley, T, Ionescu, D N

“…The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for…”
Get full text

Early-stage lung cancer—what do the experts recommend? by Leighl, N.B., Curigliano, G.

Get full text

Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation by Gosney, J.R., Paz-Ares, L., Jänne, P., Kerr, K.M., Leighl, N.B., Lozano, M.D., Malapelle, U., Mok, T., Sheffield, B.S., Tufman, A., Wistuba, I.I., Peters, S.

“…Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay…”
Get full text

Management of egfr tki-induced dermatologic adverse events by Melosky, B, Leighl, N B, Rothenstein, J, Sangha, R, Stewart, D, Papp, K

“…Targeting the epidermal growth factor receptor (egfr) pathway has become standard practice for the treatment of advanced non-small-cell lung cancer. Compared…”
Get full text

Diagnostic patterns of non-small-cell lung cancer at Princess Margaret Cancer Centre by Nadjafi, M, Sung, M R, Santos, G D C, Le, L W, Hwang, D M, Tsao, M S, Leighl, N B

“…Accurate classification of lung cancer subtypes has become critical in tailoring lung cancer treatment. Our study aimed to evaluate changes in diagnostic…”
Get full text